Oragenics (OGEN) EBITDA (2010 - 2026)
Oragenics' (OGEN) quarterly EBITDA came in at -$2.3 million in Q1 2026, down 11.34% YoY from -$2.5 million in Q1 2025, and up 9.7% on a QoQ basis from -$2.5 million in Q4 2025.
Oragenics (OGEN) EBITDA (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of EBITDA data on file, last reported at -$2.3 million in Q1 2026.
- Quarterly EBITDA fell 11.34% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.6 million (up 5.26% YoY) and the FY2025 annual result came in at -$9.4 million, up 11.33% from the prior year.
- EBITDA rose to -$2.3 million in Q1 2026, from -$2.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.7 million in Q2 2025 to a low of -$12.8 million in Q4 2023.
- A 5-year average of -$3.4 million and a median of -$2.5 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA plunged 456.56% — and 2024, when it surged 73.78%.
- Tracing OGEN's EBITDA over 5 years: stood at -$2.3 million in 2022, then sank by 456.56% to -$12.8 million in 2023, then surged by 73.78% to -$3.4 million in 2024, then advanced by 25.54% to -$2.5 million in 2025, then rose by 9.7% to -$2.3 million in 2026.
- The last three EBITDA figures came in at -$2.3 million (Q1 2026), -$2.5 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | -2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.59 Mn |
| Mar 31, 2026 | -2.26 Mn |
| Dec 31, 2025 | -2.50 Mn |
| Sep 30, 2025 | -3.12 Mn |
| Jun 30, 2025 | -1.71 Mn |
| Mar 31, 2025 | -2.03 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | -12.80 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -3.11 Mn |
| Mar 31, 2023 | -2.90 Mn |
| Dec 31, 2022 | -2.30 Mn |
| Sep 30, 2022 | -3.91 Mn |
| Jun 30, 2022 | -3.60 Mn |
| Mar 31, 2022 | -4.61 Mn |
| Dec 31, 2021 | -2.30 Mn |
| Sep 30, 2021 | -4.39 Mn |